Telapristone

Telapristone

Systematic (IUPAC) name
[(8S,11R,13S,14S,17R)-11-[4-(Dimethylamino)phenyl]-17-(2-methoxyacetyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
Clinical data
Legal status	Investigational
Identifiers
CAS Number	198414-31-2
PubChem	CID: 9806190
ChemSpider	7981950 Y
UNII	1K9EYK92PQ Y
Synonyms	CDB-4124; 17α-Acetoxy-21-methoxy-11β-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione)
Chemical data
Formula	C31H39NO5
Molecular mass	505.65 g/mol
SMILES O=C5\C=C3/C(=C2/[C@@H](c1ccc(N(C)C)cc1)C[C@@]4([C@@](OC(=O)C)(C(=O)COC)CC[C@H]4[C@@H]2CC3)C)CC5
InChI InChI=1S/C31H39NO5/c1-19(33)37-31(28(35)18-36-5)15-14-27-25-12-8-21-16-23(34)11-13-24(21)29(25)26(17-30(27,31)2)20-6-9-22(10-7-20)32(3)4/h6-7,9-10,16,25-27H,8,11-15,17-18H2,1-5H3/t25-,26+,27-,30-,31-/m0/s1 Y Key:JVBGZFRPTRKSBB-MJBQOYBXSA-N Y
(verify)

Telapristone (INN), as telapristone acetate (proposed trade names Proellex, Progenta; former code name CDB-4124), is an investigational selective progesterone receptor modulator (SPRM) being studied for the treatment of certain progesterone-sensitive conditions. It was originally developed by the National Institutes of Health (NIH), and as of 2012, is in phase II clinical trials for the treatment of uterine fibroids and endometriosis. In addition to its actions as an SPRM, telapristone also has some antiglucocorticoid activity.

See also

• Aglepristone
• Mifepristone